From Our Partners
Wednesday, June 22, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

Scientists Uncover How Ebola Disables Immune Response

by Global Biodefense Staff
August 15, 2014

Researchers have revealed how Ebola blocks and disables the body’s natural immune response. Understanding how Ebola disarms immune defenses will be crucial in the development of new treatments for the disease.

Dr. Gaya Amarasinghe and colleagues from Washington University School of Medicine along with collaborators from the Icahn School of Medicine at Mount Sinai and UT Southwestern Medical Center at Dallas show how the Ebola protein VP24 disrupts the cell’s innate immune response, a crucial early step on the virus’s path to causing deadly disease.

The results were published this week in the Cell Press journal Cell Host & Microbe.

“We’ve known for a long time that infection with Ebola obstructs an important immune compound called interferon,” said Amarasinghe. “Now we know how Ebola does this, and that can guide the development of new treatments.”

According to the researchers, VP24 works by preventing the transcription factor STAT1, which carries interferon’s antiviral message, from entering the nucleus and initiating an immune response. As part of a rapid immune response, the cell allows STAT1 an “emergency access lane” to the nucleus. Rather than block all nuclear transfer, however, VP24 focuses on blocking STAT1’s “emergency access lane.”

“Normally interferon causes STAT1 to enter the cell nucleus, where it activates the genes for hundreds of proteins involved in antiviral responses,” Dr. Daisy Leung from Washington University School of Medicine said. “But when VP24 is attached to STAT1, it can’t get into the nucleus.”

“One of the key reasons that Ebola virus is so deadly is because it disrupts the body’s immune response to the infection,” said Dr. Chris Basler of the Icahn School of Medicine at Mount Sinai. “Figuring out how VP24 promotes this disruption will suggest new ways to defeat the virus.”

These findings come at a critical time for Ebola research. If researchers carry out further study of VP24, it can open the door to new possibilities for disarming the protein’s effect on immune response.

Read more at Cell Host & Microbe: Ebola Virus VP24 Targets a Unique NLS Binding Site on Karyopherin Alpha 5 to Selectively Compete with Nuclear Import of Phosphorylated STAT1.

From Our Partners
Tags: AntiviralsEbolaEmerging ThreatsVaccines

Related Posts

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Pathogens

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Johns Hopkins: Chemical in Leafy Greens May Slow Growth of Coronaviruses
Pathogens

Johns Hopkins: Chemical in Leafy Greens May Slow Growth of Coronaviruses

April 11, 2022
New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs
Medical Countermeasures

New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs

April 10, 2022
Load More

Latest News

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Biodefense Headlines – 16 June 2022

Biodefense Headlines – 16 June 2022

June 16, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC